
Formalin-fixed, paraffin-embedded human Lung Carcinoma stained with SOX2 Mouse Monoclonal Antibody (SOX2/1792).

Western Blot of Recombinant SOX2 protein fragment and NCCIT cell lysate using SOX2 Mouse Monoclonal Antibody (SOX2/1792).

Formalin-fixed, paraffin-embedded human Cervical Carcinoma stained with SOX2 Mouse Monoclonal Antibody (SOX2/1792).

Formalin-fixed, paraffin-embedded Mouse Stomach stained with SOX2 Mouse Monoclonal Antibody (SOX2/1792).

Formalin-fixed, paraffin-embedded Mouse Intestine stained with SOX2 Mouse Monoclonal Antibody (SOX2/1792).

SDS-PAGE Analysis Purified SOX2 Mouse Monoclonal Antibody (SOX2/1792). Confirmation of Integrity and Purity of Antibody.

Analysis of Protein Array containing more than 19,000 full-length human proteins using SOX2 Mouse Monoclonal Antibody (SOX2/1792) Z- and S- Score: The Z-score represents the strength of a signal that a monoclonal antibody (MAb) (in combination with a fluorescently-tagged anti-IgG secondary antibody) produces when binding to a particular protein on the HuProtTM array. Z-scores are described in units of standard deviations (SDÂ’s) above the mean value of all signals generated on that array. If targets on HuProtTM are arranged in descending order of the Z-score, the S-score is the difference (also in units of SDÂ’s) between the Z-score. S-score therefore represents the relative target specificity of a MAb to its intended target. A MAb is considered to specific to its intended target, if the MAb has an S-score of at least 2.5. For example, if a MAb binds to protein X with a Z-score of 43 and to protein Y with a Z-score of 14, then the S-score for the binding of that MAb to protein X is equal to 29.
SOX2 is required for stem cell maintenance in the central nervous system, and it also regulates gene expression in the stomach. SOX2 is necessary for regulating multiple transcription factors that affect Oct 3/4 expression. An essential function of SOX2 is to stabilize embryonic stem cells in a pluripotent state by maintaining the requisite level of Oct 3/4 expression. Reportedly, SOX2 is associated with aggressive phenotypes of breast, head and neck, gastric, colorectal, bladder, and small cell lung cancers. However, SOX2 is expressed in a high percentage of lung squamous cell carcinomas and has been shown to be an independent favorable prognostic marker.
There are no reviews yet.